DSGN Design Therapeutics
- 3.380
- -0.160-4.52%
Design Therapeutics News
Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Piper Sandler: Upgraded the Design Therapeutics (DSGN.US) rating from neutral to incremental, and adjusted the target price from $6.00 to $12.00.
Buy Rating Justified by Design Therapeutics' Innovative Pipeline and Solid Financials
Design Therapeutics Analyst Ratings
Hold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program Updates
Design Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Diamedica Therapeutics (DMAC), Design Therapeutics (DSGN) and MiMedx Group (MDXG)
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Design Therapeutics (DSGN) Gets a Hold From Piper Sandler
Hold Rating on Design Therapeutics Amid Mixed Efficacy Data, Strategic Realignment and Financial Uncertainties
Design Therapeutics Analyst Ratings
RBC Cuts Price Target on Design Therapeutics to $4 From $7 Amid Limited Near-Term Clinical Updates, Keeps Sector Perform, Speculative Risk
Wedbush Cuts Design Therapeutics to Neutral, Cites Ataxia Drug Setback
SVB Leerink Downgrades Design Therapeutics to Market Perform, Announces $6 Price Target
Design Therapeutics Analyst Ratings
RBC Downgrades Design Therapeutics to Sector Perform From Outperform, Cuts Price Target to $7 From $23 Amid 'Limited Near-Term Catalysts,' Keeps Speculative Risk
Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN)
Piper Sandler Remains a Buy on Design Therapeutics (DSGN)
SVB Securities Reaffirms Their Buy Rating on Design Therapeutics (DSGN)
Analysis
Price Target
No Data
